{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:40:23Z","timestamp":1790030423811,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ijantimicag.2015.12.016","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T12:15:19Z","timestamp":1453551319000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Repurposing auranofin for the treatment of cutaneous staphylococcal infections"],"prefix":"10.1016","volume":"47","author":[{"given":"Shankar","family":"Thangamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F.N.","family":"Abushahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0217-0084","authenticated-orcid":false,"given":"Tiago J.P.","family":"Sobreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2015.12.016_bib0175","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1086\/533593","article-title":"Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0180","doi-asserted-by":"crossref","first-page":"11596","DOI":"10.1038\/srep11596","article-title":"Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0185","doi-asserted-by":"crossref","first-page":"e69508","DOI":"10.1371\/journal.pone.0069508","article-title":"Local inflammation exacerbates the severity of Staphylococcus aureus skin infection","volume":"8","author":"Montgomery","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/CMR.18.3.521-540.2005","article-title":"Recognition of Staphylococcus aureus by the innate immune system","volume":"18","author":"Fournier","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2015.12.016_bib0195","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1086\/598187","article-title":"Patients at risk of complications of Staphylococcus aureus bloodstream infection","volume":"48","author":"del Rio","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0200","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccc.2013.03.008","article-title":"Staphylococcus aureus bacteremia, risk factors, complications, and management","volume":"29","author":"Keynan","year":"2013","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0205","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/AAC.01587-10","article-title":"Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children","volume":"55","author":"McNeil","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 7","key":"10.1016\/j.ijantimicag.2015.12.016_bib0210","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1093\/cid\/cir164","article-title":"Characterization of global patterns and the genetics of fusidic acid resistance","volume":"52","author":"Farrell","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0215","first-page":"1162","article-title":"Dalbavancin or oritavancin for skin infections","volume":"371","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0220","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0225","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2174\/1381612821666150310104416","article-title":"Drug repurposing for the treatment of staphylococcal infections","volume":"21","author":"Thangamani","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0230","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0235","doi-asserted-by":"crossref","first-page":"e0133877","DOI":"10.1371\/journal.pone.0133877","article-title":"Repurposing clinical molecule ebselen to combat drug resistant pathogens","volume":"10","author":"Thangamani","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0240","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.2174\/1381612821666150506154434","article-title":"Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections","volume":"21","author":"Younis","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0245","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Debnath","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0250","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1073\/pnas.1504022112","article-title":"Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis","volume":"112","author":"Harbut","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0255","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00775-009-0466-z","article-title":"Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au\u2013Se adduct","volume":"14","author":"Jackson-Rosario","year":"2009","journal-title":"J Biol Inorg Chem"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0260","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/jac\/dkv163","article-title":"Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections","volume":"70","author":"Aguinagalde","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0265","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10534-014-9743-6","article-title":"Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections","volume":"27","author":"Cassetta","year":"2014","journal-title":"Biometals"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jinorgbio.2014.05.008","article-title":"Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains","volume":"138","author":"Hokai","year":"2014","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0275","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. Document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0280","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/DDDT.S72129","article-title":"Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection","volume":"8","author":"Mohamed","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0285","doi-asserted-by":"crossref","first-page":"16407","DOI":"10.1038\/srep16407","article-title":"Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0290","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","article-title":"Repurposing celecoxib as a topical antimicrobial agent","volume":"6","author":"Thangamani","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0295","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"Meletiadis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0300","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13445","article-title":"Aspergillomarasmine A overcomes metallo-\u03b2-lactamase antibiotic resistance","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ja.2014.142","article-title":"Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci","volume":"68","author":"Mohammad","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0310","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nature12790","article-title":"Activated ClpP kills persisters and eradicates a chronic biofilm infection","volume":"503","author":"Conlon","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0315","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1210\/jc.2007-0453","article-title":"Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes","volume":"92","author":"Jialal","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0320","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0325","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jac\/dks384","article-title":"Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies","volume":"68","author":"Hu","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0330","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1128\/AAC.01803-10","article-title":"Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections","volume":"55","author":"Huang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0335","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0966-842X(00)01913-2","article-title":"Mechanisms of biofilm resistance to antimicrobial agents","volume":"9","author":"Mah","year":"2001","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.12.016_bib0340","first-page":"2208","article-title":"Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study","volume":"22","author":"Egsmose","year":"1995","journal-title":"J Rheumatol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T20:52:33Z","timestamp":1537044753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916000121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0924857916000121"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing auranofin for the treatment of cutaneous staphylococcal infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}